pubmed-article:6473541 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:6473541 | lifeskim:mentions | umls-concept:C0022658 | lld:lifeskim |
pubmed-article:6473541 | lifeskim:mentions | umls-concept:C0023194 | lld:lifeskim |
pubmed-article:6473541 | lifeskim:mentions | umls-concept:C2612891 | lld:lifeskim |
pubmed-article:6473541 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
pubmed-article:6473541 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:6473541 | pubmed:dateCreated | 1984-10-19 | lld:pubmed |
pubmed-article:6473541 | pubmed:abstractText | The authors present data from a group of 55 patients suffering from chronic renal diseases. Twenty-two were treated by haemodialysis; the rest had serum creatinine levels ranging from normal to 950 mumol/l. The molar esterification rats [MER] and total cholesterol [TCH] values decreased parallel to the gradual extinction of renal function. A reduced fractional esterification rate [FER] was found in about two thirds of the dialysed patients and in about half of those whose kidney function was still relatively well preserved. It can thus be concluded that reduction of FER values indicative of a disturbance of cholesterol metabolism can already be detected in the early stages of chronic nephropathies. | lld:pubmed |
pubmed-article:6473541 | pubmed:language | eng | lld:pubmed |
pubmed-article:6473541 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6473541 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:6473541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6473541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6473541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6473541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6473541 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:6473541 | pubmed:issn | 0369-9463 | lld:pubmed |
pubmed-article:6473541 | pubmed:author | pubmed-author:StríbrnáJJ | lld:pubmed |
pubmed-article:6473541 | pubmed:author | pubmed-author:DobiásováMM | lld:pubmed |
pubmed-article:6473541 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:6473541 | pubmed:volume | 33 | lld:pubmed |
pubmed-article:6473541 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:6473541 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:6473541 | pubmed:pagination | 224-9 | lld:pubmed |
pubmed-article:6473541 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:meshHeading | pubmed-meshheading:6473541-... | lld:pubmed |
pubmed-article:6473541 | pubmed:year | 1984 | lld:pubmed |
pubmed-article:6473541 | pubmed:articleTitle | Lecithin cholesterol acyltransferase activity in chronic nephropathies. | lld:pubmed |
pubmed-article:6473541 | pubmed:publicationType | Journal Article | lld:pubmed |